Free Access
Med Sci (Paris)
Volume 30, Number 5, Mai 2014
Page(s) 493 - 495
Section Nouvelles
Published online 13 June 2014
  1. Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol 2009 ; 118 : 5–36. [CrossRef] [PubMed] [Google Scholar]
  2. Campion D, Hannequin D. La duplication du gène APP cause de maladie d’Alzheimer associée à une importante angiopathie amyloïde. Med Sci (Paris) 2006 ; 22 : 468–469. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  3. Braak H, Alafuzoff I, Arzberger T, et al. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006 ; 112 : 389–404. [CrossRef] [PubMed] [Google Scholar]
  4. Helmer C, Pasquier F, Dartigues JF. Épidémiologie de la maladie d’Alzheimer et des syndromes apparentés. Med Sci (Paris) 2006 ; 22 : 288–296. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  5. Cuvillier O, Pirianov G, Kleuser B, et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996 ; 381 : 800–803. [CrossRef] [PubMed] [Google Scholar]
  6. Couttas TA, Kain N, Daniels B, et al. Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer’s disease pathogenesis. Acta Neuropathol Commun, 2014 ; 2 : 9. [CrossRef] [PubMed] [Google Scholar]
  7. Ceccom J, Loukh N, Lauwers-Cances V, et al. Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer’s disease. Acta Neuropathol Commun, 2014 ; 2 : 12. [CrossRef] [PubMed] [Google Scholar]
  8. Pitson SM. Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem Sci 2011 ; 36 : 97–107. [CrossRef] [PubMed] [Google Scholar]
  9. Cuvillier O. Les récepteurs de la sphingosine 1-phosphate. De la biologie à la physiopathologie Med Sci (Paris) 2012 ; 28 : 951–957. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  10. Brizuela L, Ader I, Mazerolles C, et al. First evidence of sphingosine 1-phosphate lyase protein expression and activity downregulation in human neoplasm: implication for resistance to therapeutics in prostate cancer. Mol Cancer Ther 2012 ; 11 : 1841–1851. [CrossRef] [PubMed] [Google Scholar]
  11. Gosselet F. Apolipoprotéine E et intégrité de la barrière hémato-encéphalique. Med Sci (Paris) 2012 ; 28 : 920–923. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  12. Mielke MM, Lyketsos CG. Alterations of the sphingolipid pathway in Alzheimer’s disease: new biomarkers and treatment targets? Neuromolecular Med 2010 ; 12 : 331–340. [CrossRef] [PubMed] [Google Scholar]
  13. Gomez-Brouchet A, Pchejetski D, Brizuela L, et al. Critical role for sphingosine kinase-1 in regulating survival of neuroblastoma cells exposed to amyloid-beta peptide. Mol Pharmacol 2007 ; 72 : 341–349. [CrossRef] [PubMed] [Google Scholar]
  14. Hemmati F, Dargahi L, Nasoohi S, et al. Neurorestorative effect of FTY720 in a rat model of Alzheimer’s disease: Comparison with Memantine. Behav Brain Res 2013 ; 252C : 415–421. [CrossRef] [Google Scholar]
  15. Kanno T, Nishizaki T, Proia RL, et al. Regulation of synaptic strength by sphingosine 1-phosphate in the hippocampus. Neuroscience 2010 ; 171 : 973–980. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.